Generic Name: selumetinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Koselugo is a kinase inhibitor approved for treatment of children with neurofibromatosis type 1 who have inoperable neurofibromas (nerve tumors).

General Info

Koselugo is blocks the action of MEK 1 and 2, enzymes that play a role in tumor growth. The Phase II SPRINT trial showed that Koselugo shrank tumors in 66% of children with neurofibromatosis type 1 with inoperable plexiform neurofibromas. It was first approved in April 2020.


Dosing Info:

Koselugo is taken as a capsule twice daily on an empty stomach.

Side Effects

Common side effects include nausea, vomiting, diarrhea, abdominal pain, muscle and bone pain, headaches, fatigue, dry skin, rash, mouth sores, nail problems and itching. Potential serious side effects may include heart muscle problems, eye problems and vision changes, severe diarrhea, severe skin rash and lab test abnormalities.

For More Info:

Patient Assistance Program Info:

Last Reviewed: April 13, 2020